Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24258612 | 1.00 | ENPP1 (0.44) | ENPP1POLBP2RY1P2RY12DNPH1 | |
| SCHEMBL22349189 | 0.88 | POLB (0.51) | ENPP1POLBP2RY1P2RY12DNPH1 | |
| SCHEMBL24679775 | 0.85 | POLB (0.40) | ENPP1POLBP2RY1DNPH1PRKAB2 | |
| SCHEMBL24680973 | 0.78 | POLB (0.49) | ENPP1POLBP2RY1P2RY12DNPH1 | |
| SCHEMBL21299334 | 0.78 | POLB (0.50) | ENPP1POLBP2RY1DNPH1PRKAB2 | |
| SCHEMBL24444146 | 0.77 | STING1 (0.45) | ENPP1POLBP2RY1DNPH1PRKAB2 | |
| SCHEMBL21299326 | 0.76 | POLB (0.49) | ENPP1POLBP2RY1P2RY12DNPH1 | |
| SCHEMBL22268138 | 0.76 | POLB (0.50) | ENPP1POLBP2RY1P2RY2 | |
| SCHEMBL22268149 | 0.75 | POLB (0.49) | ENPP1POLBP2RY1P2RY2 | |
| SCHEMBL20691954 | 0.74 | NT5E (0.51) | P2RY1DNPH1PRKAB2TRPM2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | ENPP1 45/4885POLB 30/4885P2RY1 1124/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | ENPP1 45/4885POLB 30/4885P2RY1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.